Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5699047 | Clinical Oncology | 2012 | 13 Pages |
Abstract
Defining the target for head and neck radiotherapy is a critical issue with the introduction of steep dose gradients associated with intensity-modulated radiotherapy. Tumour delineation inaccuracies are a major source of error in radiotherapy planning. The integration of 18-fluoride fluorodeoxyglucose positron emission tomography (18FDG-PET) and magnetic resonance imaging directly into the radiotherapy planning process has the potential to greatly improve target identification/selection and delineation. This raises a range of new issues surrounding image co-registration, delineation methodology and the use of functional data and treatment adaptation. This overview will discuss the practical aspects of integrating 18FDG-PET and magnetic resonance imaging into head and neck radiotherapy planning.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
R.J.D. Prestwich, J. Sykes, B. Carey, M. Sen, K.E. Dyker, A.F. Scarsbrook,